Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-Mutant Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 0 results

Early research (Phase 1)Ended earlyNCT05153408
What this trial is testing

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Who this might be right for
Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more
Blueprint Medicines Corporation 20
Early research (Phase 1)Study completedNCT02191891
What this trial is testing

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 32
Testing effectiveness (Phase 2)Study completedNCT02803203
What this trial is testing

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Who this might be right for
Non-small Cell Lung CancerEGFR-mutant Lung Cancers
Memorial Sloan Kettering Cancer Center 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT03909334
What this trial is testing

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationAdvanced Cancer+1 more
Xiuning Le 160
Testing effectiveness (Phase 2)UnknownNCT02146118
What this trial is testing

A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma

Who this might be right for
Carcinoma, Non-Small-Cell Lung
MedicalLogic 42
Early research (Phase 1)Ended earlyNCT06685718
What this trial is testing

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerLung CancerNSCLC+3 more
BeOne Medicines 33
Testing effectiveness (Phase 2)Looking for participantsNCT07073365
What this trial is testing

Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

Who this might be right for
Non-Small Cell Lung CancerEpidermal Growth Factor Receptor
Pusan National University Hospital 70
Testing effectiveness (Phase 2)Study completedNCT01573702
What this trial is testing

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
Non Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT03586453
What this trial is testing

Osimertinib In EGFR Mutant Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Dana-Farber Cancer Institute 30
Not applicableStudy completedNCT05934461
What this trial is testing

A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer

Who this might be right for
The Primary Study Metric is Progression-free Survival (PFS)
Laibin People's Hospital 48
Not applicableStudy completedNCT06131645
What this trial is testing

IASLC Grading System as a Predictor for EGFR-TKI Therapy

Who this might be right for
Lung Cancer
Fudan University 2,160
Not applicableNot Yet RecruitingNCT05998993
What this trial is testing

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)

Who this might be right for
EGF-R Positive Non-Small Cell Lung CancerNon Small Cell Lung CancerEGFR Exon 19 Deletion+2 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT05773092
What this trial is testing

Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Who this might be right for
NSCLC
National Cancer Centre, Singapore 30
Testing effectiveness (Phase 2)Study completedNCT04147351
What this trial is testing

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Who this might be right for
NSCLC Stage IIIB~IV
National Taiwan University Hospital 22